Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Author(s): Seetha Monrad, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Noncommercial–Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/ We have reviewed this material in accordance with U.S. Copyright Law and have tried to maximize your ability to use, share, and adapt it. The citation key on the following slide provides information about how you may share and adapt this material. Copyright holders of content included in this material should contact [email protected] with any questions, corrections, or clarification regarding the use of content. For more information about how to cite these materials visit http://open.umich.edu/education/about/terms-of-use. Any medical information in this material is intended to inform and educate and is not a tool for self-diagnosis or a replacement for medical evaluation, advice, diagnosis or treatment by a healthcare professional. Please speak to your physician if you have questions about your medical condition. Viewer discretion is advised: Some medical content is graphic and may not be suitable for all viewers. Citation Key for more information see: http://open.umich.edu/wiki/CitationPolicy Use + Share + Adapt { Content the copyright holder, author, or law permits you to use, share and adapt. } Public Domain – Government: Works that are produced by the U.S. Government. (17 USC § 105) Public Domain – Expired: Works that are no longer protected due to an expired copyright term. Public Domain – Self Dedicated: Works that a copyright holder has dedicated to the public domain. Creative Commons – Zero Waiver Creative Commons – Attribution License Creative Commons – Attribution Share Alike License Creative Commons – Attribution Noncommercial License Creative Commons – Attribution Noncommercial Share Alike License GNU – Free Documentation License Make Your Own Assessment { Content Open.Michigan believes can be used, shared, and adapted because it is ineligible for copyright. } Public Domain – Ineligible: Works that are ineligible for copyright protection in the U.S. (17 USC § 102(b)) *laws in your jurisdiction may differ { Content Open.Michigan has used under a Fair Use determination. } Fair Use: Use of works that is determined to be Fair consistent with the U.S. Copyright Act. (17 USC § 107) *laws in your jurisdiction may differ Our determination DOES NOT mean that all uses of this 3rd-party content are Fair Uses and we DO NOT guarantee that your use of the content is Fair. To use this content you should do your own independent analysis to determine whether or not your use will be Fair. Autoantibodies and Rheumatologic Diseases: When and How to Use Laboratory tests Seetha Monrad M.D. Fall 2009 Case 1 23 year old woman is referred to your clinic to “rule out lupus” History is notable for no photosensitivity, unusual rashes, oral ulcers, pleurisy, hair loss, or arthralgias On family history, has an aunt with Sjögren’s disease and a cousin with lupus Physical exam completely within normal limits Outside labwork: ANA 1:40 Does she have SLE? Autoantibodies Autoantibodies are immunoglobulins that bind to antigens originating in the same individual or species (autoantigens) Autoantigens include self molecules in the nucleus, cytoplasm, and cell surface Many autoantibodies are associated with autoimmune diseases but the majority of autoantibodies have no known pathogenic role in any disease Antinuclear antibodies (ANA) Serologic hallmark of autoimmune diseases May bind DNA, RNA, nuclear proteins, protein-nucleic acid complexes Adapted from American Rheumatism Association Glossary Committee: Dictionary of the Rheumatic Diseases, vol II, Diagnostic Testing. Contact Associates PERIPHERAL Source Undetermined (All Images) ANA in non-rheumatologic diseases Hashimoto’s thyroiditis 40-50% Graves’ disease 50% Autoimmune hepatitis 60-90% Primary biliary cirrhosis 10-40% Chronic infectious diseases Mononucleosis Hepatitis C Subacute bacterial endocarditis TB Normal Population 5% Higher in women, elderly ANA in rheumatologic diseases SLE Drug-induced SLE RA (40%) Polymyositis/dermatomyositis What else? (75%) Case 2 A 40 year old woman presents with “hand pain” 6 months ago noted fingers changing colors, associated with pain Two months ago fingers became diffusely swollen, painful, difficult to move Noticing a little difficulty breathing American College of Rheumatology Source Undetermined Systemic sclerosis Generalized disorder of connective tissue Characterized clinically by thickening and fibrosis of the skin (scleroderma) Distinctive forms of involvement of internal organs, notably the heart, lungs, kidneys, and gastrointestinal tract scleroderma (Greek skleros ["hard"] + derma ["skin"]) “Scleroderma is one of the most terrible of all human ills. Like Tithonus to “wither slowly”, and like him to be “beaten down and marred and wasted” until one is literally a mummy, encased in an ever shrinking, slowly contracting skin of steel, is a fate not pictured in any tragedy, ancient or modern.” - Osler, 1898 Classification With diffuse cutaneous scleroderma Skin thickening present on the trunk in addition to face, proximal and distal extremities With limited cutaneous scleroderma Skin thickening limited to sites distal to the elbow and knee but also involving the face and neck Synonym: CREST syndrome (C, calcinosis; R, Raynaud's phenomenon; E, esophageal dysmotility; S, sclerodactyly; T, telangiectasias) Raynaud’s phenomenon American College of Rheumatology American College of Rheumatology Triphasic color change: white, blue, red Primary: common, benign, affects young women, precipitated by cold/stress More likely to be secondary (pathologic) with: older age at onset, few fingers involved, prolonged painful ischemic episodes, abnormal nailfold capillary exam Nailfold capillaroscopy Top: normal symmetric hairpin loops. Center: tortuosity and redundancy of multiple capillary loops might be encountered in both systemic sclerosis and other connective tissue disorders Bottom: disease-specific changes of systemic sclerosis, including a paucity of capillary loops (drop-out) and grossly dilated loops Journal of Musculoskeletal Medicine Sclerodactyly Source Undetermined American College of Rheumatology (Both Images) Digital ischemia American College of Rheumatology (All Images) Calcinosis cutis American College of Rheumatology (Both Images) Cutaneous findings American College of Rheumatology (All Images) Vasculopathy Source Undetermined Marked intimal hyperplasia causing lumenal occlusion Source Undetermined Scleroderma renal crisis: used to be most feared complication and major cause of mortality – less common now Pulmonary fibrosis and pulmonary hypertension American College of Rheumatology Gastrointestinal manifestations American College of Rheumatology American College of Rheumatology Systemic Sclerosis Autoantibodies ANA: 85% Anti-centromere: limited cutaneous Anti-Scl-70: diffuse scleroderma Treatments GERD: PPI, non-drug therapies GI dysmotility: prokinetics Alveolitis: steroids, immunosuppressives Pulm HTN: similar to idiopathic Renal: ACE inhibitors Raynaud’s phenomenon Treatment Behavioral modification Warm extremities AND core Avoid smoking Medications Calcium channel blockers (felodipine, amlodipine) ACE-inhibitors, angiotensin receptor blockers Selective serotonin reuptake inhibitors Phosphodiesterase inhibitors (sildenafil) Topical nitrates For severe (digital ischemia): Iloprost (intravenous prostacyclin agonist) Bosentan (endothelin receptor blocker) Sympathetic block/ sympathectomy Case 4 A 60 year old woman comes to clinic to establish care No major complaints On careful ROS, you elicit that she often feels like she has gravel in her eyes, and uses eye drops four times a day She also has a history of numerous dental caries Exam: Parotid gland enlargement Conjunctival erythema Extremely dry oral mucosa American College of Rheumatology Sjögren’s Syndrome Affects 500,000 to 2 million people in US A major women’s health issue Of increasingly important in an aging population Often overlooked and neglected Holds clues for both autoimmunity and cancer Dry mouth and dry eyes (oral and ocular sicca) Extraglandular manifestations Overlap with other diseases Rheumatic: RA, SLE Thyroiditis, primary biliary cirrhosis, multiple sclerosis Hepatitis C Lymphoproliferative disorder Sjögren’s Syndrome: Ocular manifestations Foreign body sensation, like sand in eyes Inability to tolerate contact lenses Redness, ocular fatigue Thick mucous strands in the morning Objective: Schirmer’s testing, Rose-Bengal staining American College of Rheumatology Source Undetermined Sjögren’s Syndrome: Oral manifestations American College of Rheumatology Dry mouth; carry water bottles, water at bedside “Cracker sign”: unable to eat dry food without liquid Poor dentition; unable to wear dentures Oral candidiasis Classification Criteria for Sjögren’s Syndrome* I II III IV V VI Ocular symptoms Oral symptoms Ocular signs Histopathology Salivary gland involvement Autoantibodies *The presence of 4 out of 6 criteria, including 1 objective criterion (histopathology or autoantibodies). Exclusions include HIV infection, lymphoma, GVHD, sarcoidosis. Source Undetermined (All Images) Autoantibodies in Sjogren’s syndrome ANA: ~67% Anti Ro/SSA: Recognize cellular proteins with M.W. ~52-60kDa Associated with Sjogren’s (75% primary, 15% secondary), SLE (50%) Subacute cutaneous lupus, neonatal lupus and congenital heartblock 0.1-0.5% normal adults Anti-La/SSB: Almost always associated with anti-Ro (except in primary biliary cirrhosis and autoimmune hepatitis) Associated with Sjogren’s (40%), SLE (15%), and neonatal lupus Anti-Ro/La and Neonatal Lupus Syndromes From transplacental passage of maternal anti-Ro/La in the perinatal period Transient rash Congenital heart block ~1% rate of CHB in Ro +ve mothers ~15% rate of CHB in second child most often identified between 18-24 wks gestation ~50% of asymptomatic mothers with children who have neonatal lupus will eventually develop an autoimmune disease such as lupus or Sjogren’s Source Undetermined Treatment of Sjögren’s Syndrome Ocular manifestations Artificial tears Punctal plugging Topical cyclosposrine Oral sicca Good dental hygiene Avoid anticholinergic drugs Saliva substitutes Stimulate salivary flow Sugar free candy/gum Muscarinic agonists Treat oral candidiasis NSAIDs Corticosteroids Hydroxychloroquine Immunosuppressives e.g. methotrexate, cyclophosphamide Back to case 1…. 23 year old woman is referred to your clinic to “rule out lupus” History is notable for no photosensitivity, unusual rashes, oral ulcers, pleurisy, hair loss, or arthralgias On family history, has an aunt with Sjögren’s disease and a cousin with lupus Physical exam completely within normal limits Outside labwork: ANA 1:40 Patient does not have lupus ANA is low titer; likely false positive Alternately, may reflect autoimmunity in her family Case 4 The same woman returns two years later, complaining of fatigue, arthralgias ANA drawn 2 weeks ago was >1:2560 What lab would be consistent as part of a diagnosis of lupus? 1. Anti-Ro Ab 2. Anti-phospholipid Ab 3. Anti – dsDNA 4. Anti – Sm 5. Low C3 Specific antinuclear antibodies Anti- dsDNA antibodies Highly specific for SLE Specific assays Farr Crithidia Levels fluctuate over time Serum levels may correlate with renal disease activities Have been isolated from glomerular elutes from patients with active nephritis ?Pathogenic Specific antinuclear antibodies ENA: extractable nuclear antigens Anti-Sm Smith antigen: snRNP (small nuclear ribonucleoprotein) core proteins Highly specific for SLE; sensitivity 30% Levels remain fairly constant and do not fluctuate with disease activity Anti-RNP Present in SLE (30-40%) High titers mixed connective tissue disease Anti-Histone Antibodies >95% cases of drug-induced lupus Procainamide Hydralazine Phenytoin Isoniazid Also seen in idiopathic SLE (70%) Anti-Phospholipid (APL) Antibodies Can be ‘primary’ or associated with a connective tissue disease e.g. SLE 4 subtypes False positive VDRL Lupus anticoagulants Anticardiolipin antibodies Anti-β2-glycoprotein antibodies Associated with arterial/venous thrombosis, recurrent fetal loss, thrombocytopenia Clinical use of complements in SLE C3, C4 Low levels can indicate active disease Don’t order CH50; screens for deficiency in complement cascade Low complements can also be seen in other conditions (cryoglobulinemic vasculitis, Sjogren’s etc.) Other labs often ordered Erythrocyte sedimentation rate (ESR) The rate (mm/hr) at which anticoagulated blood settles in a special tube (Westegren tube) Estimate for normal value: = [age(yrs) + 10 (if female)] 2 Inflammation increased plasma proteins and fibrinogen (acute phase reactants) cause RBCs to stick together and fall faster higher ESR Source Undetermined ESR Indirect marker of inflammation dependent on size, shape and number of RBCs presence of other plasma components (ie immunoglobulins) Affected by age and gender Responds slowly to inflammatory stimuli Inflammatory markers Acute phase proteins Produced by hepatocytes Acute phase response: increase in serum proteins in response to cytokine release (esp. IL-6) from monocytes and macrophages in inflammatory states CRP: Precise function unknown; activates complement, but also anti-inflammatory Rapidly fluctuates in response to inflammation Others: serum amyloid A (SAA), ferritin Summary Autoantibodies are confirmatory but rarely diagnostic Often are epiphenomena Know which lab abnormalities tend to be present in different diseases, but don’t rely on them exclusively Additional Source Information for more information see: http://open.umich.edu/wiki/CitationPolicy Slide 7: Adapted from American Rheumatism Association Glossary Committee: Dictionary of the Rheumatic Diseases, vol II, Diagnostic Testing. Contact Associates Slide 8: Source Undetermined (All Images) Slide 11: American College of Rheumatology; Source Undetermined Slide 14: American College of Rheumatology; American College of Rheumatology Slide 15: Journal of Musculoskeletal Medicine Slide 16: American College of Rheumatology (Both Images); Source Undetermined Slide 17: American College of Rheumatology (All Images) Slide 18: American College of Rheumatology (Both Images) Slide 19: American College of Rheumatology (All Images) Slide 20: Source Undetermined; Source Undetermined Slide 21: American College of Rheumatology Slide 22: American College of Rheumatology; American College of Rheumatology Slide 25: American College of Rheumatology Slide 27: Source Undetermined; American College of Rheumatology Slide 28: American College of Rheumatology Slide 29: Source Undetermined (All Images) Slide 31: Source Undetermined Slide 41: Source Undetermined